City Cancer Challenge (C/Can) shared on LinkedIn:
“In Concepción, 130+ professionals from the local oncology network and specialists from six countries came together for the Multidisciplinary Cancer Management Course (MCMC), delivered by City Cancer Challenge (C/Can) and the American Society of Clinical Oncology (ASCO), with the Biobío Regional Health Secretariat (SEREMI de Salud del Biobío) and partners across the regional and national cancer ecosystem.
Over three days, specialists from Chile, the United States, Mexico, Colombia, Costa Rica, and Uruguay worked alongside local teams on real challenges in breast and colorectal cancer, and on strengthening Oncology Committees and Multidisciplinary Teams.
What set this edition apart was local leadership and ownership at every step. The programme, priority topics, case selection, and methodology were shaped by a local Organising Committee and Scientific Committee working hand in hand with C/Can and ASCO, ensuring international expertise was grounded in the priorities of Concepción’s oncology network.
Because international expertise can support a city, but it cannot replace local leadership.
This reflects a core principle of C/Can’s work: equitable, sustainable solutions can’t simply be transferred from one country to another. They’re built with local stakeholders and complemented by international collaboration.
The MCMC is part of the C/Can City Programme in Concepción, launched in 2024. To date, 14 institutions, 120+ professionals, and 370+ patients have contributed to an assessment of cancer care in the city, identifying capacities, gaps, and opportunities for improvement.
Building on these lessons, C/Can will continue working with its partners and the local oncology network to turn priorities into concrete solutions that strengthen the cancer care system.
Strengthening a health system is not only about increasing capacity. It is about ensuring that those capacities work together to deliver better outcomes for people.”
You can also read: U.S. Government Introduces Policy to Stop High-Risk Life Sciences Research
